MapLight Therapeutics, Inc.
MapLight Therapeutics (Nasdaq: MPLT) is a clinical-stage biopharmaceutical company developing medicines for debilitating central nervous system disorders. Its discovery platform uses optogenetics and transcriptomic technologies to identify disease-related neural circuits and drug targets. The lead candidate,… From the company’s description.
In fiscal 2025, MapLight Therapeutics, Inc. reported a net loss of $161.15M. Operations used $138.14M in cash.
Dotted labels explain each measure.
What MapLight Therapeutics, Inc. does
In the company’s own words
MapLight Therapeutics (Nasdaq: MPLT) is a clinical-stage biopharmaceutical company developing medicines for debilitating central nervous system disorders. Its discovery platform uses optogenetics and transcriptomic technologies to identify disease-related neural circuits and drug targets. The lead candidate, ML-007C-MA, combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic and is in Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis. ML-004, a 5-HT1B/1D agonist formulation, is in Phase 2 development for social communication deficits in autism spectrum disorder; additional programs target other neuropsychiatric conditions and Parkinson’s disease. MapLight retains global development and commercial rights to its programs. Its website is https://maplighttherapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1770069
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MapLight Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MapLight Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MapLight Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MapLight Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MapLight Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”